Education
About Us
Working with TipRanks
Follow Us
Day One Biopharmaceuticals (DAWN)
NASDAQ:DAWN
DAWN Stock Chart & Stats
$10.37
-$0.14(-1.13%)
At close: 4:00 PM EST
$10.37
-$0.14(-1.13%)
Day’s Range― - ―
52-Week Range$5.64 - $13.20
Previous CloseN/A
Volume175.11K
Average Volume (3M)2.21M
Market Cap
$1.10B
Enterprise Value$834.01M
Total Cash (Recent Filing)$441.11M
Total Debt (Recent Filing)$2.79M
Price to Earnings (P/E)―
Beta1.18
Next Earnings
May 13, 2026EPS Estimate
-0.28Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.21
Shares Outstanding105,704,636
10 Day Avg. Volume1,939,913
30 Day Avg. Volume2,207,614
Financial Highlights & Ratios
PEG Ratio-4.58
Price to Book (P/B)2.18
Price to Sales (P/S)6.09
P/FCF Ratio-9.26
Enterprise Value/Market Cap0.76
Enterprise Value/Revenue5.27
Enterprise Value/Gross Profit5.92
Enterprise Value/Ebitda-7.88
Forecast
1Y Price Target
$22.14Price Target Upside113.50% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
EPS Forecast (FY)-0.47
Revenue Forecast (FY)$236.56M
Bulls Say, Bears Say
Bulls Say
Balance Sheet StrengthAnalyst emphasizes that a strong cash position should fund ongoing commercialization and development programs without immediate need for additional financing, reducing dilution risk and supporting execution.
Clinical Development ReadoutsAnalyst notes that upcoming early-stage clinical data for pipeline candidates and the FIREFLY-1 readout could clarify development plans and materially broaden long-term growth drivers if results are favorable.
Commercial AdoptionAnalyst highlights that strong commercial execution for Ojemda has driven rapid adoption and improved physician familiarity, with many patients remaining on therapy beyond imaging-defined progression, supporting sustained revenue growth.
Bears Say
Competitive And Scientific RiskAnalyst cautions that multiple peers pursuing B7-H4 therapies and prior discontinuation of a similar program raise competitive and scientific uncertainty for the company's antibody-drug conjugate efforts.
Development Timeline And Operating ExpenseAnalyst notes that a pushed-back launch for a partnered program combined with updated operating expense trends increases near-term development risk and heightens financial pressure on the company.
Profitability PressureAnalyst warns that higher research and selling expenses tied to clinical activity are reducing earnings and creating a near-term profitability headwind.
Day One Biopharmaceuticals News
DAWN FAQ
What was Day One Biopharmaceuticals’s price range in the past 12 months?
Day One Biopharmaceuticals lowest stock price was $5.63 and its highest was $13.20 in the past 12 months.
What is Day One Biopharmaceuticals’s market cap?
Day One Biopharmaceuticals’s market cap is $1.10B.
When is Day One Biopharmaceuticals’s upcoming earnings report date?
Day One Biopharmaceuticals’s upcoming earnings report date is May 13, 2026 which is in 70 days.
How were Day One Biopharmaceuticals’s earnings last quarter?
Day One Biopharmaceuticals released its earnings results on Feb 24, 2026. The company reported -$0.21 earnings per share for the quarter, missing the consensus estimate of -$0.149 by -$0.061.
Is Day One Biopharmaceuticals overvalued?
According to Wall Street analysts Day One Biopharmaceuticals’s price is currently Undervalued.
Does Day One Biopharmaceuticals pay dividends?
Day One Biopharmaceuticals does not currently pay dividends.
What is Day One Biopharmaceuticals’s EPS estimate?
Day One Biopharmaceuticals’s EPS estimate is -0.28.
How many shares outstanding does Day One Biopharmaceuticals have?
Day One Biopharmaceuticals has 105,704,636 shares outstanding.
What happened to Day One Biopharmaceuticals’s price movement after its last earnings report?
Day One Biopharmaceuticals reported an EPS of -$0.21 in its last earnings report, missing expectations of -$0.149. Following the earnings report the stock price went down -9.068%.
Which hedge fund is a major shareholder of Day One Biopharmaceuticals?
Currently, no hedge funds are holding shares in DAWN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Day One Biopharmaceuticals Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$22.14 (113.50% Upside)
$22.14 (113.50% Upside)
Blogger Sentiment
Bullish
DAWN Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 859.4K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.0%
Last 30 Days ▼ 2.9%
Last 30 Days ▼ 2.9%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
14.45%
12-Months-Change
Fundamentals
Return on Equity
-22.74%
Trailing 12-Months
Asset Growth
-12.86%
Trailing 12-Months
Company Description
Day One Biopharmaceuticals
Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genetically defined cancers. Its lead product candidate is DAY101, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/progressive low-grade glioma. The company is also developing Pimasertib, an oral small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.
DAWN Company Deck
DAWN Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call highlights strong commercial momentum for Ojemda with exceptional revenue growth (FY2025 revenue up 172% YoY; Q4 sequential growth of 37%), robust prescription trends (>4,600 scripts, +180% YoY) and a solid balance sheet (~$441M cash, no debt). Clinical readouts (FIREFLY-1 three-year data) provide compelling efficacy and long TTNT supporting clinical value, and the Mersana acquisition adds a promising near-term pipeline asset (EMILY) with mid-2026 data expected. Offsetting risks include pediatric safety considerations (decreased growth velocity, anemia, occasional severe rash), concentration on a single marketed product, expected gross-to-net pressure in 2026 (guidance rising to 16%–19%), and timing/regulatory uncertainties for pipeline readouts (FIREFLY-2 top-line mid-2027, EMILY data mid-2026). Overall the positives — strong commercial execution, clear growth guidance, healthy payer coverage, and a strong cash position — outweigh the challenges, though pipeline timing and safety management remain important watchpoints.View all DAWN earnings summariesDAWN Stock 12 Month Forecast
Average Price Target
$22.14
▲(113.50% Upside)
Technical Analysis
Theravance Biopharma
―
Kura Oncology
―
Gossamer Bio
―
Maravai Lifesciences Holdings
―
Septerna, Inc.
―
Ownership Overview
1.60% Insiders
16.63% Mutual Funds
13.04% Other Institutional Investors
55.90% Public Companies and
Individual Investors